论文部分内容阅读
目的探讨StarClose血管闭合器在肝脏恶性肿瘤患者动脉化疗栓塞(TACE)后闭合穿刺点的效果。方法 2008年1月至2009年12月共有117例肝脏恶性肿瘤患者TACE治疗后使用StarClose血管闭合器闭合穿刺点。对这些患者的临床资料进行回顾性分析。结果 117例患者共进行了273次TACE,并于术后使用StarClose血管闭合器闭合穿刺点。266次闭合器使用后止血效果满意,满意率为97.4%。经统计学分析,首次使用闭合器与重复使用闭合器止血成功率及在不同股动脉穿刺部位的止血成功率差异均无统计学意义。随访过程(3～4周)中无严重并发症发生。结论 StarClose血管闭合器用于肝脏恶性肿瘤患者TACE后闭合穿刺点安全可行。
Objective To investigate the effect of closure of StarClose vessel occluder after arterial chemoembolization (TACE) in patients with hepatic malignant tumors. Methods From January 2008 to December 2009 a total of 117 patients with hepatic malignancies were treated with StarClose vascular occluder closure puncture after TACE treatment. The clinical data of these patients were retrospectively analyzed. Results A total of 273 TACEs were performed in 117 patients and the puncture site was closed using a StarClose vascular closure device after surgery. Satisfactory results were obtained after 266 times of closure, with a satisfactory rate of 97.4%. After statistical analysis, the first use of the closure and re-use of closure device hemostatic success rate and in different femoral artery puncture site hemostasis success rate differences were not statistically significant. No serious complications occurred during follow-up (3-4 weeks). Conclusion The StarClose vessel occluder is safe and feasible for the closure puncture of TACE in patients with hepatic malignant tumors.